Cargando...
Effectiveness and safety of benralizumab for severe asthma in clinical practice (J-BEST): a prospective study
BACKGROUND: Benralizumab is a humanized, fucosylated, monoclonal antibody that targets the interleukin 5 (IL-5) α receptor. Several phase III trials have shown that benralizumab can significantly reduce the incidence of acute exacerbations and improve lung function in patients with severe asthma. Ho...
Gardado en:
| Publicado en: | Ann Transl Med |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
AME Publishing Company
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7210162/ https://ncbi.nlm.nih.gov/pubmed/32395482 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm.2020.04.01 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|